You are here

  • Home
  • Archive
  • Volume 81, Issue 10
  • Anti-inflammatory action of colchicine in hospitalised patients with COVID-19. Response to: ‘Colchicine treatment in community healthcare setting to prevent severe COVID-19’ by Della-Torre et al

Article Text

Article menu
Download PDFPDF
Correspondence response
Anti-inflammatory action of colchicine in hospitalised patients with COVID-19. Response to: ‘Colchicine treatment in community healthcare setting to prevent severe COVID-19’ by Della-Torre et al
  1. Silvia Piantoni1,2,
  2. Enrico Colombo3,4,
  3. Roberto Furloni3,4,
  4. Laura Andreoli1,2,
  5. Antonio Brucato5,
  6. Massimo Imazio6,
  7. Paolo Airó1,
  8. Mirko Scarsi3,4
  1. 1 Rheumatology and Clinical Immunology Unit, ASST Spedali Civili, Brescia, Italy
  2. 2 Department of Clinical and Experimental Sciences, University of Brescia, Brescia, Italy
  3. 3 Internal Medicine Department, ASST Valcamonica, Esine (Brescia), Italy
  4. 4 COVID Unit, ASST Valcamonica, Esine (Brescia), Italy
  5. 5 Department of Biomedical and Clinical Sciences “Sacco”, University of Milano, Ospedale Fatebenefratelli, Milano, Italy
  6. 6 University Cardiology, A.O.U. Città della Salute e della Scienza di Torino, Torino, Italy
  1. Correspondence to Dr Silvia Piantoni, Rheumatology and Clinical Immunology Unit, Department of Clinical and Experimental Sciences, ASST Spedali Civili and University of Brescia, Brescia, Italy; slv.piantoni{at}gmail.com

https://doi.org/10.1136/annrheumdis-2020-218806

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    We thank Della-Torre et al for their interest on our report on the retrospective, case-control observational study with colchicine in patients hospitalised for severe COVID-19,1 and for rising the really crucial issue of the timing of the therapeutic intervention with anti-inflammatory therapies in this disease.2

    Our observations should be interpreted in the scenario of the uncontrolled epidemic that, during March and April 2020, overwhelmed the health system in Lombardy, Italy, with rapid shortage of intensive care unit beds. As pointed out by the authors in other papers, after this period, the severity of the COVID-19 progressively decreased, in parallel with the exhaustion of the epidemic.3 4 The COVID-19 related mortality observed in our study (27.5% in the overall cohort of 262 consecutive cases; 36.4% in the standard of care group, and 15.8% in …

    View Full Text

    Footnotes

    • PA and MS are joint senior authors.

    • Handling editor Josef S Smolen

    • Twitter @piantoni_silvia, @lauraandreoli80

    • PA and MS contributed equally.

    • Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

    • Competing interests None declared.

    • Patient and public involvement Patients and/or the public were not involved in the design, or conduct, or reporting, or dissemination plans of this research. Refer to the Methods section for further details.

    • Provenance and peer review Commissioned; internally peer reviewed.

    Linked Articles